STRIDES PHARMA SCIENCE
|
STRIDES PHARMA SCIENCE Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -7.68 | -22.44 | -51.25 | 29.93 | 4.06 |
| CEPS(Rs) | 7.85 | 1.37 | -26.87 | 50.19 | 24.23 |
| DPS(Rs) | 2.50 | 1.50 | - | 2.50 | 14.00 |
| Book NAV/Share(Rs) | 230.95 | 242.83 | 262.48 | 309.09 | 281.55 |
| Tax Rate(%) | -27.01 | 19.32 | 27.32 | 11.49 | 20.71 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.73 | 6.17 | -0.40 | 11.45 | 10.95 |
| EBIT Margin(%) | 3.16 | -0.40 | -8.93 | 7.77 | 4.47 |
| Pre Tax Margin(%) | -1.87 | -4.58 | -12.25 | 5.03 | 1.16 |
| PAT Margin (%) | -2.38 | -3.70 | -8.90 | 4.45 | 0.92 |
| Cash Profit Margin (%) | 1.15 | 0.20 | -4.53 | 8.22 | 4.61 |
| Performance Ratios | |||||
| ROA(%) | -2.49 | -3.52 | -6.99 | 3.82 | 0.63 |
| ROE(%) | -6.88 | -10.15 | -18.49 | 9.21 | 1.68 |
| ROCE(%) | 4.15 | -0.49 | -9.49 | 9.08 | 4.06 |
| Asset Turnover(x) | 1.05 | 0.95 | 0.78 | 0.86 | 0.68 |
| Sales/Fixed Asset(x) | 2.02 | 1.91 | 1.75 | 2.04 | 1.43 |
| Working Capital/Sales(x) | 69.65 | 43.06 | -106.88 | 69.38 | -27.04 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.52 | 0.57 | 0.49 | 0.70 |
| Receivable days | 71.28 | 73.25 | 79.41 | 68.09 | 74.33 |
| Inventory Days | 66.36 | 67.80 | 81.35 | 66.13 | 64.17 |
| Payable days | 204.02 | 230.40 | 267.95 | 264.54 | 274.24 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | 28.21 | 79.39 |
| PCE(x) | 99.68 | 209.18 | -12.90 | 16.83 | 13.31 |
| Price/Book(x) | 3.39 | 1.18 | 1.32 | 2.73 | 1.15 |
| Yield(%) | 0.32 | 0.52 | - | 0.30 | 4.34 |
| EV/Net Sales(x) | 2.32 | 1.37 | 1.86 | 2.86 | 1.68 |
| EV/Core EBITDA(x) | 12.03 | 9.69 | 51.09 | 13.84 | 8.11 |
| EV/EBIT(x) | 47.67 | -201.23 | -12.01 | 22.32 | 21.93 |
| EV/CE(x) | 2.07 | 1.01 | 0.85 | 1.39 | 0.77 |
| M Cap / Sales | 1.78 | 0.70 | 1.01 | 2.28 | 1.05 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 9.83 | 20.13 | -7.41 | 20.49 | 26.33 |
| Core EBITDA Growth(%) | 50.42 | 365.23 | -83.70 | 20.61 | 100.96 |
| EBIT Growth(%) | 888.18 | 94.73 | -211.81 | 102.24 | 48.50 |
| PAT Growth(%) | 35.67 | 51.31 | -294.53 | 462.28 | -51.42 |
| EPS Growth(%) | 65.76 | 56.22 | -271.23 | 636.70 | -88.79 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.14 | 1.27 | 1.18 | 0.76 | 0.78 |
| Current Ratio(x) | 1.03 | 1.05 | 0.99 | 1.03 | 0.93 |
| Quick Ratio(x) | 0.64 | 0.67 | 0.64 | 0.59 | 0.62 |
| Interest Cover(x) | 0.63 | -0.10 | -2.69 | 2.84 | 1.35 |
| Total Debt/Mcap(x) | 0.34 | 1.07 | 0.90 | 0.28 | 0.68 |
Compare Financial Ratios of peers of STRIDES PHARMA SCIENCE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| STRIDES PHARMA SCIENCE | ₹6,364.6 Cr | -6.4% | -51.2% | 22.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹429,361.0 Cr | -1.4% | 1.2% | 46.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,274.0 Cr | -1.4% | 1.8% | 60% | Stock Analytics | |
| CIPLA | ₹117,144.0 Cr | -0.3% | -3.3% | 19.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,134.0 Cr | 0.8% | 1.8% | 13.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,554.4 Cr | -1.7% | 1.2% | 53.9% | Stock Analytics | |
STRIDES PHARMA SCIENCE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| STRIDES PHARMA SCIENCE | -6.4% |
-51.2% |
22.7% |
| SENSEX | -1% |
3.9% |
16% |
You may also like the below Video Courses
